[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

FirstWord: Market Research Reports

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:

  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.


FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Publications found: 700
Sort by:
Breast Cancer: KOL Insight [2018] US$ 8,495.00

... triple-negative breast cancer and the potential usage of PD-1/PD-L1 checkpoint inhibitors is also explored. Twelve US and EU KOLs offer their candid insights on these ... how checkpoint inhibitors may be used in triple-negative breast cancer (TNBC). What are KOLs’ thoughts on these agents and how do they ...

April 2018
Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018] US$ 8,495.00

... therapies set to revolutionise NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all ... how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic Steatohepatitis (NASH). Take a tour of the report now The table ...

April 2018
Dark Analytics: Shining a Torch for Pharma US$ 395.00

... understanding HCP prescribing behaviour and refining sales strategies. In Dark Analytics: Shining a torch for pharma we interviewed leading experts to help you ... that could frustrate the development of dark analytics? What dark analytics experts say 'The implications of dark data for pharma are profound. So ...

April 2018
New Commercial Models: Benchmarking Pharma Companies [2018] US$ 2,495.00

... directly quoted comments Example insight included in New Commercial Models: Benchmarking Pharma Companies New business models bring about a culture of innovation and ... products and therapy areas.' The expert panel for New Commercial Models: Benchmarking Pharma Companies Indranil Bagchi, VP & Franchise Head, ...

April 2018
Paying for Digital Health: Payer Insights US$ 2,495.00

... these key questions we interviewed eight US and European payer experts to reveal in Paying for Digital Health – Payer Insights the specific technologies, funding strategies and operational ...

April 2018
Biosimilars: US Payer Perspectives (2018) US$ 2,495.00

... 2018). You won't find entrenched perceptions, old data and out-of-date opinions. Instead, Biosimilars: US Payer Perspectives ... Example insight included in Biosimilars: US Payer Perspectives Payers have devised strategies to encourage the adoption of biosimilars. Currently, payers require prior authorisations, ...

March 2018
Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018] US$ 8,495.00

... Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines had on treatment practice? New guidelines on COPD patient assessment, segmentation ... US KOL. Professor of Medicine, and former Chief, Division of Pulmonary Diseases and Critical Care Medicine, at a leading respiratory hospital in the ...

March 2018
Prostate Cancer: Update Bulletin #2 [April 2018] US$ 1,095.00

... opinion leader (KOL) insights on the latest events happening in the prostate cancer space. Topics covered include expert opinions on the FDA approval ... inhibitor Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC), data published from the PROSPER study for Pfizer ...

March 2018
Targeted Therapies in Asthma: Update Bulletin #2 [April 2018] US$ 1,095.00

... the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy? Do KOLs think that Elayta’s mechanism of action is compatible with it having ... AMBAR trial meeting its primary endpoint and plasma exchange therapy with Albutein/IVIG being successfully marketed?

March 2018
COPD: KOL Insight US$ 8,495.00

... therapies approved in Europe) carve themselves out a niche? KOLs also offer fresh insight on the continued development of biologic treatment options (e.g. anti ... Disease (GOLD) guidelines had on treatment practice? New guidelines on COPD patient assessment, segmentation and treatment were published in 2017, so ...

March 2018
Market Access Impact: Renal Cell Carcinoma (US) 2018 US$ 5,345.00

... ; Pfizer) Torisel (temsirolimus; Pfizer) Votrient (pazopanib; Novartis) Exploring Market Access Barriers Market Access Impact: Renal Cell Carcinoma (US) [2018] explores key issues affecting RCC drug manufacturers ...

March 2018
Market Access Impact: Renal Cell Carcinoma (EU5) 2018 US$ 5,345.00

... ) Torisel (temsirolimus; Pfizer) Votrient (pazopanib; Novartis) Exploring Important Market Access Issues Market Access Impact: Renal Cell Carcinoma (EU5) explores key issues affecting RCC drug manufacturers ...

March 2018
Benchmarking Key Account Management Capabilities US$ 1,495.00

... on all cylinders? If, not, why not? What makes a great KAM (Key Account Manager) and KAM team and what are the personal attributes ... provides the metrics for you need to evaluate and benchmark your organization's KAM capabilities. 100 KAM experts speak out on Team size ...

March 2018
Benchmarking Pharma’s MSL Capabilities US$ 2,495.00

... included in Benchmarking Pharma's MSL Capabilities The need for on-demand MSLs is rising; ... Benchmarking Pharma's MSL Capabilities Mark Rees-Saunders, Medical Affairs Excellence Lead, AstraZeneca UK Senior MSL Manager, Top 10 Pharma Company, UK MSL Director, Specialty Pharma Company, UK Carmen Sanchez Puyol, MSL ...

March 2018
Alzheimer's Disease: Update Bulletin #2 [April 2018] US$ 1,095.00

... key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa ... Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with ...

March 2018
CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018] US$ 8,495.00

... , and how they expect developers to successfully differentiate their CAR-T therapies in KOL Insight: CAR-T Therapies in Haematological Malignancy. Experts also provide their candid views on next-generation ...

March 2018
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) 2018 US$ 5,345.00

... and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (EU5) [2018]. Based on a ... Eli Lilly/Boehringer Ingelheim) Vipidia (alogliptin; Takeda) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus [Orals] (EU5) explores key ...

March 2018
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) 2018 US$ 5,345.00

... and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) [2018]. Based on a survey ... ) Tradjenta (linagliptin; Eli Lilly/Boehringer Ingelheim) Exploring Market Access Barriers Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) [2018] explores ...

March 2018
Medical Affairs in Emerging Markets US$ 2,495.00

... MA professionals from each country to reveal in Medical Affairs in Emerging Markets- BRIC the specific opportunities and challenges they ... anything related to participation in tender interactions is covered by Market Access and KAMs. Medical Affairs do not participate in negotiation activities except in cases ...

March 2018
Ovarian Cancer: KOL Insight US$ 8,495.00

... play a role? Twelve of the world’s leading KOLs from the US and Europe offer candid insights on four marketed therapies and nine Phase ... ? Could ImmunoGen’s antibody-drug conjugate IMGN853 have a potential role in ovarian cancer? KOLs debate the potential advantages and pitfalls to this novel approach ...

March 2018
Psoriasis: Update Bulletin #3 [April 2018] US$ 1,095.00

... opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; KOL views on AbbVie’s presentation of positive ... competitor to marketed biological therapies for the treatment of moderate-to-severe psoriasis? Bristol Myers Squibb’s BMS-986165 represents a novel approach ...

March 2018
Rheumatoid Arthritis: KOL Insight [2018] US$ 8,495.00

... branded anti-TNFs may face. Twelve US and European KOLs offer their candid insights on these issues and more. Take a tour of the ... Lupus Clinic, Temple University, Philadelphia, PA, USA. KOLs from Europe Prof Paul Emery, is the Arthritis Research UK Professor of Rheumatology and Director of the ...

February 2018
Head and Neck Squamous Cell Carcinoma: KOL Insight [2018] US$ 8,495.00

... transformed the second-line therapy of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and expectations are high that ... Oncology, Hospital Llobregat, Barcelona, Spain. Stephane Temam, Head of Department of Head & Neck Cancer, Gustave Roussy Institute, Villejuif, France. Anonymous German ...

February 2018
Market Access Impact: HIV (EU5) 2018 US$ 5,345.00

... your brand can do to level the playing field in Market Access Impact: HIV (EU5) [2018]. Based on a survey of 150 infectious disease ... ) Exploring Market Access Barriers Market Access Impact: HIV (EU5) explores key issues affecting HIV drug manufacturers. You’ll learn: How barriers affect market access: What ...

February 2018
Market Access Impact: HIV (US) 2018 US$ 5,345.00

... what your brand can do to level the playing field in Market Access Impact: HIV (US) [2018]. Based on a survey of 100 infectious disease ... ) Exploring Market Access Barriers Market Access Impact: HIV (US) explores key issues affecting HIV drug manufacturers. You’ll learn: How barriers affect market access: What ...

February 2018
Medical Affairs Reputations: Renal Cell Carcinoma (US) 2018 US$ 6,365.00

... ways you can improve your medical affairs services in Medical Affairs Reputations: Renal Cell Carcinoma (US). Comparing 10 major Renal Cell Carcinoma treatments from Novartis, ... team should engage. Insight into Medical Affairs Teams for These 10 Renal Cell Carcinoma Treatments Afinitor (everolimus; Novartis ...

February 2018
Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018 US$ 6,365.00

... ways you can improve your medical affair services in Medical Affairs Reputations: Renal Cell Carcinoma (EU5). Comparing 10 major Renal Cell Carcinoma treatments from Novartis, ... your team should engage. Insight into Medical Affairs Teams for These Renal Cell Carcinoma Treatments Afinitor (everolimus; Novartis) ...

February 2018
Atopic Dermatitis: Update Bulletin #2 [March 2018] US$ 1,095.00

... opinion leader (KOL) views on recent developments in the treatment of atopic dermatitis (AD). Topics covered include KOL views on; Pfizer’s announcement of initiation ... (JAK1) inhibitor PF 04965842 in the treatment of moderate to severe atopic dermatitis (AD), but how do KOLs view this novel therapy, and what ...

February 2018
Colorectal Cancer: Update Bulletin #2 [March 2018] US$ 1,095.00

... on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views ...

February 2018
KAM Metrics: Driving efficiency and measuring success US$ 2,495.00

... your time with old data and common knowledge. KAM Metrics: Driving efficiency and measuring success gives fresh new insight into ... by 129 directly quoted comments Example insight included in KAM Metrics: Driving efficiency and measuring success 'Metrics can be used to facilitate cross-functioning as well ...

February 2018
Multiple Myeloma: Update Bulletin #3 [March 2018] US$ 1,095.00

... in the treatment of multiple myeloma (MM). Topics covered include KOL views on; Celgene and bluebird bio’s presentation of updated findings from a Phase ... for the treatment of multiple myeloma there is increasing interest in exploring treatment intervention in smoldering multiple myeloma, but how do KOLs ...

February 2018
Renal Cell Carcinoma: Update Bulletin #3 [March 2018] US$ 1,095.00

... presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the success of Roche’s Phase ...

February 2018
Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2018] US$ 1,095.00

... ) from North America and Europe on a variety of recent events in the type 2 diabetes mellitus (T2DM) market, including; the European Commission’s approval of Novo Nordisk ...

February 2018
Ulcerative Colitis: Update Bulletin #2 [March 2018] US$ 1,095.00

... presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include; Celgene reporting data from a Phase ...

February 2018
Biosimilars: EU Payer Perspectives US$ 2,495.00

... relation to Humira biosimilars Future challenges and opportunities in the European biosimilars market Example insight included in Biosimilars: EU Payer Perspectives 'Aligned with ... been hugely successful.' Example quote included in Biosimilars: EU Payer Perspectives 'There have been huge cost savings over ...

January 2018
Targeted Therapies in Asthma: KOL Insight [2018] US$ 8,495.00

... how developers can differentiate their pipeline therapies in KOL Insight: Targeted Therapies in Asthma. Ten North American and European KOLs provide their insight on 3 marketed products and ...

January 2018
NPS+ Renal Cell Carcinoma (EU5) 2018 US$ 2,655.00

... more than others? There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...

January 2018
NPS+ Renal Cell Carcinoma (US) 2018 US$ 2,655.00

... than others? There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...

January 2018
NPS+ HIV (EU5) 2018 US$ 2,655.00

... how does each of the leading brands compare to its competitors? NPS+ HIV (EU5) gives a unique insight into the overall brand health of 11 leading ... in the world.We conducted the survey between February 6-14, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...

January 2018
NPS+ HIV (US) 2018 US$ 2,655.00

... is ‘useful but very expensive’? Explore Important Brand Loyalty Issues NPS+ HIV (US) offers valuable insight into brand loyalty from the perspective ... in the world.We conducted the survey between February 6-14, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...

January 2018
Market Access Impact: Psoriasis (US) 2018 US$ 5,345.00

... your brand can do to level the playing field in Market Access Impact: Psoriasis (US) [2018]. Based on a survey of 100 dermatologists ... Market Access Barriers Market Access Impact: Psoriasis (US) explores key issues affecting Psoriasis drug manufacturers. You’ll learn: How barriers affect market access: ...

January 2018
Market Access Impact: Psoriasis (EU5) 2018 US$ 5,345.00

... help the last place brand double its share in Market Access Impact: Psoriasis (EU5) [2018]. Based on a survey of 150 ... Exploring Market Access Barriers Market Access Impact: Psoriasis (EU5) explores key issues affecting Psoriasis drug manufacturers. You’ll learn: How barriers affect market access: What ...

January 2018
Acute Myeloid Leukaemia:KOL Insight US$ 8,495.00

... they expect developers to differentiate their pipeline therapies in KOL Insight: Acute Myeloid Leukaemia. Twelve US and European KOLs give their insight on six marketed products and 13 pipeline programmes ...

January 2018
Glioblastoma: KOL Insight US$ 8,495.00

... the market? Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 ... are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ...

January 2018
Market Access Impact: Melanoma (EU5) 2018 US$ 5,345.00

... help the last place brand double its share in Market Access Impact: Melanoma (EU5) [2018]. Based on a survey of 150 oncologists ... (vemurafenib; Roche) Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands do ...

January 2018
Market Access Impact: Melanoma (US) 2018 US$ 5,345.00

... what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018]. Based on a survey of 100 oncologists and ... ; Roche) Market Access Impact: Melanoma (US) [2018] explores key issues affecting melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands ...

January 2018
Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018 US$ 6,365.00

... competition? Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: NSCLC (EU5). Comparing 11 major NSCLC treatments from Roche ...

January 2018
Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (US) 2018 US$ 6,365.00

... competition? Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: NSCLC (US). Comparing 13 major NSCLC treatments from ARIAD Pharmaceuticals ...

January 2018
Medical Affairs Reputations: Psoriasis (EU5) 2018 US$ 6,365.00

... stacks up to the market leader. In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (EU5). Comparing 12 major Psoriasis treatments from AbbVie, Biogen, Celgene, ...

January 2018
Medical Affairs Reputations: Psoriasis (US) 2018 US$ 6,365.00

... come out on top? In the US, nearly all of the psoriasis medical affairs teams we surveyed are running neck and neck with at least ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (US). Comparing 11 major psoriasis treatments from AbbVie, Amgen, Celgene, Eli ...

January 2018

Filters

Search

Categories

1
43
3
2
3
2
1
16
1
1
8
2
4
1
19
1
1
1
2
31
6
24
62
10
455

Publishers

700

Regions

2
1
15
1
1
14
4
1
660
1

Price

Date

Pages

Offers